Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gut Microbes Could Enable Early Detection and Treatment of Pancreatic Cancer

By HospiMedica International staff writers
Posted on 13 Jun 2025

Pancreatic cancer remains one of the most serious and challenging diseases in oncology due to its difficulty in detection and limited treatment options. More...

Now, a new international collaborative study suggests that in the future, early-stage pancreatic cancer could potentially be identified through the analysis of gut microbes. These microbes may also present new opportunities for developing therapies.

In this study, researchers from the University of Jyväskylä (Jyväskylä, Finland) and their collaborators analyzed the gut microbiota of over 180 pancreatic cancer patients from Finland and Iran, along with healthy individuals from the same regions. They discovered consistent microbial patterns associated with pancreatic cancer regardless of the patients' geographic or ethnic backgrounds. Compared to the healthy group, the intestinal microbiota of pancreatic cancer patients contained significantly more facultative pathogens and notably fewer beneficial bacteria. Specifically, a decline was observed in helpful bacteria from the Clostridia class, such as the butyric acid–producing Lachnospiraceae, Butyricicoccaceae, and Ruminococcaceae. In contrast, higher levels of potential pathogens like Enterobacteriaceae, Enterococcaceae, and Fusobacteriaceae were found in the gut flora of those with pancreatic cancer.

Based on these findings, the researchers propose that future investigations should explore whether these beneficial microbes could be developed into a new class of probiotics—live microbial products—that could be used alongside standard chemotherapy. This combination could potentially offer a more precise and effective method for treating pancreatic cancer. At the same time, the researchers stress the importance of conducting additional studies in varied populations to validate these results. Furthermore, they created a statistical model using microbiome data, which may eventually assist in predicting pancreatic cancer. This marks a promising initial step toward achieving earlier diagnosis of the disease.

“The findings on beneficial Clostridia are interesting because it has been shown earlier that ordinary Clostridiales populations effectively mediate anti-canceric immune reactions against solid tumors,” said Satu Pekkala, Senior Lecturer from the Faculty of Sport and Health Sciences, University of Jyväskylä.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.